BEZ235 (NVP-BEZ235, Dactolisib)

Catalog No.S1009

BEZ235 (NVP-BEZ235, Dactolisib) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell.

Price Stock Quantity  
USD 110 In stock
USD 170 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

BEZ235 (NVP-BEZ235, Dactolisib) Chemical Structure

BEZ235 (NVP-BEZ235, Dactolisib) Chemical Structure
Molecular Weight: 469.55

Validation & Quality Control

Cited by 81 publications:

8 customer reviews :

Quality Control & MSDS

Related Compound Libraries

BEZ235 (NVP-BEZ235, Dactolisib) is available in the following compound libraries:

PI3K Inhibitors with Unique Features

Product Information

  • Compare PI3K
    Compare PI3K Products
  • Research Area
  • Inhibition Profile
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description BEZ235 (NVP-BEZ235, Dactolisib) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell.
Targets p110α [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
mTOR (p70S6K) [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)

 View  More

IC50 4 nM 5 nM 6 nM 7 nM
In vitro BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. [1] BEZ235 is an mTORC1/2 catalytic inhibitor. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
Trypanosoma brucei bruceiNFrqd3pCdnSrbXnjdo9jcWGuIFHzd4F6M1HkV|E5KGh?MkjBSG1UVw>?NIrJ[4RCdnSrdIL5dIFvd3OxbXHsJIFkfGm4aYT5JJdqfGhiRVO1NEBw\iByLkCwNlUh|ryPNFLSTW4zPDhyNUm0Oi=>
MCF7NX25c4U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\YNE4xOS1zMECg{txOM2L3PFQ5KGh?MYHEUXNQMULJR|UxRTBwN{Og{txOMVSyN|g4OTlyNB?=
HCT116NIPzVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYSwMlAyNTFyMDFOwG0>M{m5VVQ5KGh?MmHrSG1UVw>?NH74TFJKSzVyPUGuNVYh|ryPM2rCcFI{QDdzOUC0
U87MGNFe5TYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXywMlAyNTFyMDFOwG0>NHjGSFA1QCCqNFrrWZBFVVORMn7tTWM2OD1zLkOyJO69VQ>?MnzPNlM5PzF7MES=
HBC4NWTXOGlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NID3elkxNjBzLUGwNEDPxE1?NH7WWG81QCCqNUG5NGlyVG:pIFfJOVA:NThwNkGgUS=>MkTVNlI{OzZ{NE[=
BSY1NXr4SlVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XRSFAvODFvMUCwJO69VQ>?M37mflQ5KGh?MW\Mc4chT0l3ME2tPE41QCCPNFTUbm4zOjN|NkK0Oi=>
HBC5NFzRNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTpN2YxNjBzLUGwNEDPxE1?MnHiOFghcA>?MV;Mc4chT0l3ME2tO{45PyCPNIO4e4EzOjN|NkK0Oi=>
MCF7MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\BcVAvODFvMUCwJO69VQ>?MnjmOFghcA>?M37WVWxw\yCJSUWwQU05NjF4IF2=MknCNlI{OzZ{NE[=
MDA-MB-231M3rhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkP5NE4xOS1zMECg{txOMnu1OFghcA>?MVLMc4chT0l3ME2tPE4xQSCPNE\rOVczOjN|NkK0Oi=>
U251NYfrV3dVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXv0NGlPOC5yMT2xNFAh|ryPM36z[lQ5KGh?MWHMc4chT0l3ME2tO{43PiCPMWSyNlM{PjJ2Nh?=
SF268MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLDNE4xOS1zMECg{txOMYq0PEBpMn7sUI9oKEeLNUC9MVcvQTJiTR?=NIHEZXAzOjN|NkK0Oi=>
SF295NH\mNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH[4T4QxNjBzLUGwNEDPxE1?M3npcVQ5KGh?NU[3d|hQVG:pIFfJOVA:NThwM{GgUS=>MX6yNlM{PjJ2Nh?=
SF539M4exe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLMNE4xOS1zMECg{txONWLsNoF2PDhiaB?=NW\oTVMyVG:pIFfJOVA:NThwNUmgUS=>NY\TR5hWOjJ|M{[yOFY>
SNB75MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIOzelIxNjBzLUGwNEDPxE1?M33LWVQ5KGh?NF3xUI5Nd2diR1m1NF0uQC53ODDNMXuyNlM{PjJ2Nh?=
SNB78NFO4dGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37EN|AvODFvMUCwJO69VQ>?NEWzPYk1QCCqNUHzbpRTVG:pIFfJOVA:NThwNkWgUS=>M3HsXVIzOzN4MkS2
HCC2998NVH6SWFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHRNnNmOC5yMT2xNFAh|ryPM1;ye|Q5KGh?NGTLUVlNd2diR1m1NF0uQC5yNTDNMmnNNlI{OzZ{NE[=
KM12Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zXelAvODFvMUCwJO69VQ>?MYC0PEBpMojQUI9oKEeLNUC9MVcvPTRiTR?=NHHxb|UzOjN|NkK0Oi=>
HT-29NVHENnQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXq0NWNoOC5yMT2xNFAh|ryPMlmyOFghcA>?NEPEenBNd2diR1m1NF0uPy55NTDNMXiyNlM{PjJ2Nh?=
HCT15NVm4UJV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnv6NE4xOS1zMECg{txONV:3NHQyPDhiaB?=MXrMc4chT0l3ME2tPE4xOyCPMX[yNlM{PjJ2Nh?=
HCT116NFLzUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXOwMlAyNTFyMDFOwG0>NEf5S5Y1QCCqMmHwUI9oKEeLNUC9MVcvPjFiTR?=M1;yVVIzOzN4MkS2
NCI-H23NVHqfm1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4m3elAvODFvMUCwJO69VQ>?NYH2cJpXPDhiaB?=Mn\rUI9oKEeLNUC9MVcvPjRiTR?=Ml\PNlI{OzZ{NE[=
NCI-H226MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVnmUZVrOC5yMT2xNFAh|ryPNWr0Wo93PDhiaB?=Mly3UI9oKEeLNUC9MVgvPDRiTR?=NH36NZQzOjN|NkK0Oi=>
NCI-H522MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;VPXF3OC5yMT2xNFAh|ryPM17zTFQ5KGh?NGDR[HlNd2diR1m1NF0uQC52NTDNMnfVNlI{OzZ{NE[=
NCI-H438Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoqwNE4xOS1zMECg{txONFrlXo81QCCqNX[5N2VMVG:pIFfJOVA:NThwMUGgUS=>NYTVemN2OjJ|M{[yOFY>
A549NUnSe2tzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjYNWsxNjBzLUGwNEDPxE1?MWO0PEBpNVfKc|M4VG:pIFfJOVA:NThwMEegUS=>M3zWbVIzOzN4MkS2
DMS273NFTR[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUSwMlAyNTFyMDFOwG0>MUK0PEBpMXjMc4chT0l3ME2tO{45OCCPM1TqUFIzOzN4MkS2
DMS114MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVKwMlAyNTFyMDFOwG0>M2X4fFQ5KGh?NWCw[284VG:pIFfJOVA:NThwM{mgUS=>MmLGNlI{OzZ{NE[=
LOXIMVIMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV2wMlAyNTFyMDFOwG0>NYD3S2NCPDhiaB?=M163R2xw\yCJSUWwQU05NjZ4IF2=NYHWdHNJOjJ|M{[yOFY>
OVCAR3NWPBV3c2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PxZVAvODFvMUCwJO69VQ>?Ml70OFghcA>?NGjrdZNNd2diR1m1NF0uQC5zNzDNNUeyc4k6OjJ|M{[yOFY>
OVCAR4NFLHV|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY[wMlAyNTFyMDFOwG0>NVy3cnltPDhiaB?=MWfMc4chT0l3ME2tPE42QCCPMmrKNlI{OzZ{NE[=
OVCAR5NITHPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\WNFAvODFvMUCwJO69VQ>?NVuzUJI{PDhiaB?=MVfMc4chT0l3ME2tO{42PyCPM13WW|IzOzN4MkS2
OVCAR8NEj2bIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGGzW|gxNjBzLUGwNEDPxE1?NVPHNJdwPDhiaB?=MoiyUI9oKEeLNUC9MVcvQDRiTR?=MXKyNlM{PjJ2Nh?=
SKOV3M4DkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnyNE4xOS1zMECg{txOMWe0PEBpM3jxb2xw\yCJSUWwQU05NjRzIF2=MkXkNlI{OzZ{NE[=
RXF631LM1rEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHWNE4xOS1zMECg{txOM3XaNlQ5KGh?Mn;FUI9oKEeLNUC9MVgvOjFiTR?=MnrzNlI{OzZ{NE[=
ACHNMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVuwMlAyNTFyMDFOwG0>NYHIbJczPDhiaB?=MXzMc4chT0l3ME2tO{46PSCPMmfBNlI{OzZ{NE[=
St-4M2TsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLHe4g3OC5yMT2xNFAh|ryPNGDVfGY1QCCqM3;Sdmxw\yCJSUWwQU04NjR5IF2=MWCyNlM{PjJ2Nh?=
MKN1NX3rN29FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLhfVR1OC5yMT2xNFAh|ryPNV;xPY1LPDhiaB?=MWDMc4chT0l3ME2tPE41OSCPM2XlPVIzOzN4MkS2
MKN7M{fhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXlS4gxNjBzLUGwNEDPxE1?M1vu[lQ5KGh?M2LlSGxw\yCJSUWwQU04NjZ6IF2=MYeyNlM{PjJ2Nh?=
MKN28MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlL4NE4xOS1zMECg{txONWjrOHlKPDhiaB?=M3HCTGxw\yCJSUWwQU04NjB5IF2=M4rVWlIzOzN4MkS2
MKN45NHLGVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVOwMlAyNTFyMDFOwG0>MmnBOFghcA>?MXvMc4chT0l3ME2tPE4{PCCPNIjwbWgzOjN|NkK0Oi=>
MKN74MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYe2WVZPOC5yMT2xNFAh|ryPM17SVlQ5KGh?MXvMc4chT0l3ME2tO{41OiCPNGrEOVYzOjN|NkK0Oi=>
DU145M3jEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPaNGpHOC5yMT2xNFAh|ryPMUi0PEBpNYjE[FV1VG:pIFfJOVA:NThwMU[gUS=>MV2yNlM{PjJ2Nh?=
PC3M4Oye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV21R3pxOC5yMT2xNFAh|ryPM2D5UVQ5KGh?NUK4VZlbVG:pIFfJOVA:NThwNk[gUS=>Mn;QNlI{OzZ{NE[=
Trypanosoma brucei bruceiNV\QepZGTnWwY4Tpc44hSXO|YYm=NXXjfmlrOjByIH7NM{PLU|EzKGh?MXzEUXNQM32zWmRm[3KnYYPlJIlvKHCqb4PwbI91cWS7bDDpco9{cXSxbDDwbI9{eGijdHWgcIV3\Wx?NUT4bIprOjR6MEW5OFY>
Trypanosoma brucei bruceiMVzGeY5kfGmxbjDBd5NigQ>?NE\Fd|AyQCCqMVTEUXNQMlK3TY5pcWKrdHnvckBw\iC{ZXPldJRwei2vZXTpZZRm\CCnbnTvZ5l1d3OrczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiC2cnHud4ZmenKrbjD1dJRic2V?NHXy[|gzPDhyNUm0Oi=>
Trypanosoma brucei bruceiNYX3[Zd5TnWwY4Tpc44hSXO|YYm=MYeyNFAhdk1?M3rUUFEzKGh?MnPFSG1UVw>?NVjYfFFPTW[oZXP0JI9vKHOyaHnu[49ugWynaX6gcIV3\Wx?MlrMNlQ5ODV7NE[=
Trypanosoma brucei bruceiM1vxOmZ2dmO2aX;uJGF{e2G7M2m3XVIxOCCwTR?=NIHDOY4yOiCqNIXJSZJFVVORNFHpeVFG\m[nY4Sgc44heGixc4DoZZRq\HmuY3jvcIlv\SCuZY\lcC=>NG\PS5QzPDhyNUm0Oi=>
UM-UC-3MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTNzNTDwUS=>MlnxV2FPT0WU
SBC-1NHHNS3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTOe|hKSzVyPUe0NkBxVQ>?NXHQc4RsW0GQR1XS
MKN1NF7XW|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDLTWM2OD1{Lkigcm0>NWn0OlBEW0GQR1XS
NCI-H720MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3jcZlJUUN3ME2zMlU4KG6PNYLMPXp[W0GQR1XS
BFTC-909NHnERW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYn6cGZSUUN3ME2zMlcyKG6PNXf4eWlDW0GQR1XS
BPH-1NH:zR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTRwN{[gcm0>MVHTRW5ITVJ?
PC-3Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDJTWM2OD13LkC5JI5OMVXTRW5ITVJ?
AN3-CAMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDFTWM2OD13LkW2JI5OMVXTRW5ITVJ?
HNM1n0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\xdmlEPTB;NT65OkBvVQ>?MofLV2FPT0WU
HCC2218M1jy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU[yTIpGUUN3ME22MlYyKG6PMX;TRW5ITVJ?
KP-4MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvxfXBKSzVyPUegcm0>NHHUS3pUSU6JRWK=
LU-139M4OxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHJfGFTUUN3ME23Mlc4KG6PMmXTV2FPT0WU
ETK-1NU\RXVFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTdwOEigcm0>NWrEeZlsW0GQR1XS
Ramos-2G6-4C10M2nQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrNPZlKSzVyPUiuOFkhdk1?MYnTRW5ITVJ?
MHH-PREB-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTlwMUKgcm0>NWjuOnRLW0GQR1XS
DU-4475MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDaXoNKSzVyPUmuOFQhdk1?Mm\DV2FPT0WU
NCI-H1666MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTlwN{Ggcm0>MX7TRW5ITVJ?
CAMA-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnoS41KSzVyPUmuPEBvVQ>?M2DMWHNCVkeHUh?=
TYK-nuMl;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjKO2xKSzVyPUmuPVQhdk1?M4DZXXNCVkeHUh?=
MFE-280NEPHSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LCU2lEPTB;OT65PUBvVQ>?Ml3DV2FPT0WU
A549MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\wVWlEPTB;MUCuNVQhdk1?M1XLWHNCVkeHUh?=
769-PNFz5XG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{T4fGlEPTB;MUCuOFQhdk1?M2fFOHNCVkeHUh?=
L-363Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDwTWM2OD1zMD62PUBvVQ>?NH\xTGFUSU6JRWK=
ES8NH7NdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF:yWGFKSzVyPUGwMlkhdk1?MmH4V2FPT0WU
PA-1M{[3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mkm2TWM2OD1zMT64NkBvVQ>?M{\wZ3NCVkeHUh?=
MewoNGi2UFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTFzLkm5JI5OM4\BWHNCVkeHUh?=
HSC-3M{HHWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzFUI1KSzVyPUGyMlIyKG6PM1;EZXNCVkeHUh?=
H4M{\jeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvZeHFKSzVyPUGyMlY4KG6PMVrTRW5ITVJ?
BB65-RCCMme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnsUYZqUUN3ME2xNk44OiCwTR?=MlvQV2FPT0WU
NCI-H1793NGLHd5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnSZYNKSzVyPUGyMlgzKG6PNHr2T4tUSU6JRWK=
KARPAS-45NULGTZJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHu3UmhKSzVyPUGzMlUyKG6PNIrpUJZUSU6JRWK=
GCTMnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fvcWlEPTB;MUOuOlghdk1?MnvOV2FPT0WU
EoL-1MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M32xZ2lEPTB;MUOuPVMhdk1?NWTEU3RlW0GQR1XS
LB2241-RCCNXrnUog3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\1OIZKSzVyPUG0MlAyKG6PMXLTRW5ITVJ?
ES5MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\0d2p3UUN3ME2xOE44PCCwTR?=MV3TRW5ITVJ?
LOXIMVIM2HiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nWfGlEPTB;MUSuPVkhdk1?M1rpWXNCVkeHUh?=
COR-L105MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPnbGtFUUN3ME2xOU4xPCCwTR?=NUn3UpE6W0GQR1XS
P12-ICHIKAWAMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTF3LkGgcm0>NYDiVotbW0GQR1XS
CHL-1NV7UbGU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTF3LkS1JI5ONF7HNHZUSU6JRWK=
VMRC-RCZNYPBXopoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHUeVlKSzVyPUG1MlY{KG6PNXHxW41ZW0GQR1XS
HHMmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DifWlEPTB;MUWuO{BvVQ>?MmCxV2FPT0WU
NUGC-3M2HqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{m5d2lEPTB;MU[uN|Qhdk1?M1ziO3NCVkeHUh?=
EGI-1NFXS[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTF4LkSzJI5OM{XpUHNCVkeHUh?=
OS-RC-2MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTF4LkS3JI5ONH3iUIJUSU6JRWK=
MOLT-16NX6yS4RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTF5LkG1JI5OMoj0V2FPT0WU
NCI-H209MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XSTmlEPTB;MUeuNlkhdk1?M4XC[HNCVkeHUh?=
697NFfBR5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XZN2lEPTB;MUeuOFMhdk1?MWXTRW5ITVJ?
D-56MGNFPPPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1W1dmlEPTB;MUeuOlkhdk1?MknZV2FPT0WU
VA-ES-BJMke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\ke5FYUUN3ME2xO{45OyCwTR?=NHjN[HJUSU6JRWK=
EW-16NH7LUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTF6LkC0JI5OMV3TRW5ITVJ?
HGC-27NU\iO5hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPvTWM2OD1zOD6wOkBvVQ>?NGDablZUSU6JRWK=
ES7M2i0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;WNVNKSzVyPUG4MlA6KG6PNVHhPY1{W0GQR1XS
HuH-7MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3u5[GlEPTB;MUiuOEBvVQ>?MUnTRW5ITVJ?
BCPAPMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHrTWM2OD1zOD62OUBvVQ>?M{P5N3NCVkeHUh?=
SW1710NHja[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrQe2tDUUN3ME2xPE44OiCwTR?=MlGzV2FPT0WU
IST-MEL1Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVnPT3BZUUN3ME2xPE44PyCwTR?=NW\uTZlRW0GQR1XS
SF295MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFX2e2VKSzVyPUG4Mlk{KG6PMWnTRW5ITVJ?
RPMI-7951NVfhTFVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnieHJKSzVyPUG5MlI5KG6PNELsZVBUSU6JRWK=
SF126M335ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HOeGlEPTB;MUmuOFEhdk1?MXHTRW5ITVJ?
GAMGMl72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3hTWM2OD1zOT60PEBvVQ>?M2rpVHNCVkeHUh?=
KNS-81-FDNV71bopET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULYeXN{UUN3ME2xPU42PCCwTR?=NWLUXJA2W0GQR1XS
RT-112M2\FTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLweGM1UUN3ME2xPU43PiCwTR?=M{DCVnNCVkeHUh?=
DELMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIj6NnNKSzVyPUKwMlQ6KG6PMoe3V2FPT0WU
CGTH-W-1NGfpXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rRSGlEPTB;MkCuOlMhdk1?NVPQWZlSW0GQR1XS
HOSNF2zUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTuTWM2OD1{MT6wOkBvVQ>?NWLhem9{W0GQR1XS
ES4MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{i3emlEPTB;MkGuNFghdk1?M2Dhb3NCVkeHUh?=
RXF393MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTJzLkS1JI5OMn3vV2FPT0WU
NCI-H2030MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTJzLkWyJI5OM17MWHNCVkeHUh?=
YH-13NHnvO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\pTWM2OD1{MT64PEBvVQ>?MnuwV2FPT0WU
HT-1080M37FcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHHfVZbUUN3ME2yNU46OyCwTR?=M3\IVHNCVkeHUh?=
NCI-SNU-1NUf5fJU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13iPGlEPTB;MkGuPVUhdk1?NVvKZoZHW0GQR1XS
G-402M{DKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLCTWM2OD1{Mj6xOkBvVQ>?NXHVZYVjW0GQR1XS
786-0NGXKfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTJ{LkK5JI5OMXvTRW5ITVJ?
ME-180NELwe3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTJ{LkSzJI5OMYXTRW5ITVJ?
NB69MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTJ{LkWzJI5OMX\TRW5ITVJ?
J-RT3-T3-5MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTqRmN3UUN3ME2yNk46PiCwTR?=M1TxbHNCVkeHUh?=
TGBC1TKBMn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXrTWM2OD1{Mz6wOUBvVQ>?MXjTRW5ITVJ?
SW780NHfPXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrMV2p4UUN3ME2yN{4yOyCwTR?=NWnidVlLW0GQR1XS
MG-63NXTPOYZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkniTWM2OD1{Mz60OUBvVQ>?NFPBSHJUSU6JRWK=
BV-173MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\ETWM2OD1{Mz64O{BvVQ>?MXrTRW5ITVJ?
CAL-51NXTXc3dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7uSZdKSzVyPUKzMlg6KG6PNUPxOmdWW0GQR1XS
A375MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHmOnhKSzVyPUKzMlk{KG6PNITNUI5USU6JRWK=
MEL-HONWTnTlRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmGxTWM2OD1{ND6wOEBvVQ>?MoPKV2FPT0WU
EFO-27MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzON4NKUUN3ME2yOE4{OyCwTR?=M4nvfnNCVkeHUh?=
Hs-578-TMknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{Xm[GlEPTB;MkSuOVghdk1?NWPW[YNYW0GQR1XS
NBsusSRNV3DRmlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTJ2Lk[gcm0>MlSwV2FPT0WU
CTB-1M3;3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTJ2Lk[3JI5OMn7rV2FPT0WU
FTC-133NHPOPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrvO25xUUN3ME2yOU4yKG6PMV7TRW5ITVJ?
MOLT-4Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nRcWlEPTB;MkWuNVIhdk1?M{m2OHNCVkeHUh?=
HO-1-N-1NWThOnQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{K5W2lEPTB;MkWuNVUhdk1?NHnXT2NUSU6JRWK=
ES3M{HkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjSNpdqUUN3ME2yOU4zOiCwTR?=MkfjV2FPT0WU
TI-73NXnEU|VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPUTWM2OD1{NT6yPEBvVQ>?NIrKbZlUSU6JRWK=
MPP-89Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LDSWlEPTB;MkWuN|Ihdk1?MVfTRW5ITVJ?
KYSE-150NGLkS5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\helZKSzVyPUK1Mlg6KG6PMWjTRW5ITVJ?
LXF-289Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTJ4LkC0JI5ONIHRR2hUSU6JRWK=
SK-LU-1NXHJ[mo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLrSXlKSzVyPUK2MlE4KG6PNVXLbGFkW0GQR1XS
HOP-92MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjRTWM2OD1{Nj60PEBvVQ>?Mn\iV2FPT0WU
HuO9MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LXWWlEPTB;Mk[uO|Yhdk1?NXvY[ohHW0GQR1XS
SW962M1\z[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnv3TWM2OD1{Nj63OkBvVQ>?MYfTRW5ITVJ?
RS4-11NH2yWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnP[4JyUUN3ME2yOk46OSCwTR?=MUPTRW5ITVJ?
NCI-H292MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYe2SGg1UUN3ME2yO{BvVQ>?M123ZXNCVkeHUh?=
DBNYLuO|dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fVb2lEPTB;MkeuN|Yhdk1?MYLTRW5ITVJ?
SW1088Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;OS3FKSzVyPUK4MlI6KG6PNXjS[nF7W0GQR1XS
A204M1\idGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTJ6LkS3JI5OM2PWOnNCVkeHUh?=
A3-KAWM1vtfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTJ6Lk[0JI5OMYXTRW5ITVJ?
MV-4-11NUHxbGNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTJ6Lkegcm0>NXrKUW57W0GQR1XS
ES1M{HFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPCUHpKSzVyPUK4Mlg1KG6PMWnTRW5ITVJ?
ONS-76MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LmO2lEPTB;MkmuNFUhdk1?NWXQZ|F2W0GQR1XS
D-263MGMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHHTWM2OD1{OT6zOUBvVQ>?MXjTRW5ITVJ?
U-2-OSM3;s[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\E[HJzUUN3ME2yPU42KG6PMWnTRW5ITVJ?
T98GM17XZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\ITWM2OD1{OT64PEBvVQ>?MUHTRW5ITVJ?
GI-ME-NNWP3XYd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTJ7LkmxJI5OM3HoR3NCVkeHUh?=
BHT-101MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnOcnFKSzVyPUOwMlA2KG6PMlXIV2FPT0WU
NOS-1MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvGbolKSzVyPUOwMlEzKG6PNWOzVWNzW0GQR1XS
AsPC-1M{fWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{nIZmlEPTB;M{CuNkBvVQ>?MmrLV2FPT0WU
QIMR-WILM1PsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTNyLk[gcm0>NYXNNWhyW0GQR1XS
JVM-3NYnGPJJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvze4VLUUN3ME2zNE45OyCwTR?=NIDTS3FUSU6JRWK=
KU-19-19MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3rN4VoUUN3ME2zNU4yOyCwTR?=MVvTRW5ITVJ?
OVCAR-8NXnRS41ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTNzLkK2JI5OMkLqV2FPT0WU
BENM4\tTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTNzLk[zJI5OMYTTRW5ITVJ?
BE-13Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nweGlEPTB;M{GuPFIhdk1?NWXEbGFRW0GQR1XS
EW-18MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1viUmlEPTB;M{GuPFYhdk1?NYPNVnRPW0GQR1XS
ECC10NYP5cmtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;aVIxKSzVyPUOxMlk2KG6PMnvlV2FPT0WU
CTV-1NFnuO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\DTWM2OD1|Mj64NkBvVQ>?MWLTRW5ITVJ?
COLO-800MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmm1TWM2OD1|Mj65NkBvVQ>?M3nhfHNCVkeHUh?=
A2058MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrWZph1UUN3ME2zN{4zPSCwTR?=MoDDV2FPT0WU
VM-CUB-1M4jXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDnPXFsUUN3ME2zN{41OyCwTR?=NFPDZZdUSU6JRWK=
Ca9-22M2LSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M16yfmlEPTB;M{OuOVUhdk1?M4XxbXNCVkeHUh?=
COLO-684NV3Z[pZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTN|LkW4JI5OMmrPV2FPT0WU
RPMI-8226MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTN|LkiyJI5ONFfiTJRUSU6JRWK=
SK-NEP-1NGTuW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTiTWM2OD1|ND6xOUBvVQ>?MknFV2FPT0WU
BeckerMniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfDe21oUUN3ME2zOE4zOSCwTR?=NFXjb5dUSU6JRWK=
NCI-H28MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTN2LkS0JI5ONX3UUpBGW0GQR1XS
CAL-120NHvxemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fXUWlEPTB;M{SuO|Ihdk1?MV;TRW5ITVJ?
MDA-MB-157MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTOTWM2OD1|NT60NUBvVQ>?NGPIOWRUSU6JRWK=
OVCAR-5NH3GeJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\STWM2OD1|NT60O{BvVQ>?MWLTRW5ITVJ?
LAMA-84MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTN3Lki3JI5ONVricVlqW0GQR1XS
CAKI-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnO[YhKSzVyPUO2MlQ{KG6PM{XBXHNCVkeHUh?=
DaoyNIXqN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXj5WnMzUUN3ME2zOk44KG6PMXTTRW5ITVJ?
CAL-62NIPkT21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLxTWM2OD1|Nj64OkBvVQ>?NXjIV2ZtW0GQR1XS
8-MG-BANE\HOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2T0ZmlEPTB;M{euNlUhdk1?M3e3c3NCVkeHUh?=
8505CMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrScZlKSzVyPUO3MlUyKG6PMnvOV2FPT0WU
LNCaP-Clone-FGCMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jFNGlEPTB;M{euOVkhdk1?MlvLV2FPT0WU
CAL-39NUPDRYk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XQV2lEPTB;M{euPUBvVQ>?NYXmWoMxW0GQR1XS
MN-60NYnZXYdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTN5Lkm2JI5OMoTRV2FPT0WU
RKONEDTeXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rBSWlEPTB;M{iuN|Mhdk1?M4\TSnNCVkeHUh?=
U251NXLMcHZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3i1[2lEPTB;M{iuOFMhdk1?NVvy[YJlW0GQR1XS
SJSA-1M3XnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTN6LkW0JI5ONWC0b4xSW0GQR1XS
CAL-12TNUDzTYpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTN6Lk[gcm0>M{XkW3NCVkeHUh?=
HCC1419NFfIcnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInVOXNKSzVyPUO4MlcyKG6PMYHTRW5ITVJ?
CO-314MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTEVmVqUUN3ME2zPE44PCCwTR?=MWDTRW5ITVJ?
LB1047-RCCMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELNe5lKSzVyPUO4MlgyKG6PMlTmV2FPT0WU
A101DM1r3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17yTWlEPTB;M{iuPVchdk1?MVXTRW5ITVJ?
MDA-MB-175-VIIM1z2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTN7LkWxJI5ONVPZeHF4W0GQR1XS
MZ2-MELNXXzZnFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTN7Lk[2JI5ONXjzb5U6W0GQR1XS
NB5Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTRyLk[0JI5OMoWwV2FPT0WU
G-401MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fiWWlEPTB;NECuPFIhdk1?M2DPe3NCVkeHUh?=
HTMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH34foZKSzVyPUSxMlAzKG6PMX3TRW5ITVJ?
8305CMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjiOmFKSzVyPUSxMlg4KG6PMXfTRW5ITVJ?
BHYMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTR{LkeyJI5ONW\rSGVDW0GQR1XS
NTERA-S-cl-D1NH7j[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MluwTWM2OD12MzDuUS=>MVrTRW5ITVJ?
T-24NXPXUll4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXF[3A1UUN3ME20N{45OyCwTR?=MYHTRW5ITVJ?
EPLC-272HMofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\ZTWM2OD12ND6zPUBvVQ>?NV60[m9xW0GQR1XS
PSN1MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3mTWM2OD12ND60JI5ONV7lbIE2W0GQR1XS
NCI-H2452M{PrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nNdGlEPTB;NESuOVghdk1?MWPTRW5ITVJ?
KS-1M{TDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\yTWM2OD12ND62OkBvVQ>?MWXTRW5ITVJ?
HD-MY-ZNEHXbopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fHR2lEPTB;NESuPVIhdk1?NF72eWpUSU6JRWK=
KNS-62MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTR3LkO4JI5ONYH3[2tvW0GQR1XS
NOMO-1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vOWGlEPTB;NEWuPFchdk1?MWXTRW5ITVJ?
SK-HEP-1M{\0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\jN2lEPTB;NE[uNFQhdk1?MoTzV2FPT0WU
IGR-1NFzaWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrxdJVKSzVyPUS2MlE{KG6PM3\yNXNCVkeHUh?=
KYSE-180MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPRTWM2OD12Nj6xO{BvVQ>?MU\TRW5ITVJ?
EW-22NXX1cm5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjrcGdKSzVyPUS2MlIhdk1?MUHTRW5ITVJ?
NCI-H1355M2\VXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vncGlEPTB;NE[uN|Qhdk1?M4PuU3NCVkeHUh?=
DOHH-2NUnCWXhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYD1blFFUUN3ME20Ok4{PyCwTR?=NYHFbYZlW0GQR1XS
A4-FukMnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTR4LkWyJI5ONGDOTVZUSU6JRWK=
PC-14MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\TTWM2OD12Nj61O{BvVQ>?M2Hkb3NCVkeHUh?=
TE-5MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTR4Lki0JI5OM2PhZXNCVkeHUh?=
LB996-RCCM1TRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPxc5RKSzVyPUS3MlE6KG6PM3zRbHNCVkeHUh?=
NCI-H1623M4fJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4e4dWlEPTB;NEeuO|Yhdk1?MVvTRW5ITVJ?
NCI-H1155M1;tUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVn0SlREUUN3ME20PE4{OiCwTR?=MXfTRW5ITVJ?
LoVoMkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLldpo4UUN3ME20PE41KG6PMkTjV2FPT0WU
MCF7M1ri[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTR6LkW4JI5ONVHGUWl3W0GQR1XS
AGSMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TQWGlEPTB;NEiuO|chdk1?M1u5Z3NCVkeHUh?=
PFSK-1NWfCOHpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTR7LkC2JI5ONHHCcVBUSU6JRWK=
22RV1NWfMUY1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmn3TWM2OD12OT6wPUBvVQ>?MkXRV2FPT0WU
COR-L23NWPRT|NwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NECwdJNKSzVyPUS5MlE3KG6PNIjwdVhUSU6JRWK=
D-283MEDMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTR7Lk[xJI5OM2fZVnNCVkeHUh?=
SW982M2jwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPIOHBKSzVyPUS5MlkyKG6PNWK1Z4VuW0GQR1XS
SW620MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLi[YRKSzVyPUWwMlM3KG6PMVzTRW5ITVJ?
KYSE-140M{LuRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUD3dYpEUUN3ME21NE42PSCwTR?=NEXHW5ZUSU6JRWK=
GCIYNInzS2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2Xle2lEPTB;NUCuOlchdk1?MUnTRW5ITVJ?
MHH-ESS-1NU[4S3ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13aUGlEPTB;NUGuPVUhdk1?M4nJOnNCVkeHUh?=
D-423MGMmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHy3NodKSzVyPUWyMlA5KG6PNIHxXXRUSU6JRWK=
SF539M2q3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13BVGlEPTB;NUKuN|Uhdk1?NIfkNZNUSU6JRWK=
RPMI-2650MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTV{Lk[5JI5OMl7VV2FPT0WU
GR-STNWPnOolVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\oTWM2OD13Mj64O{BvVQ>?M1XBcHNCVkeHUh?=
YKG-1M4XEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDWTWM2OD13MzDuUS=>Mm\PV2FPT0WU
SK-MES-1NGm5XHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWmycXNiUUN3ME21N{4zPiCwTR?=MXrTRW5ITVJ?
HLENET5NmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPtbo9KSzVyPUWzMlQ4KG6PMkfsV2FPT0WU
RVH-421M4f0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHYe3F[UUN3ME21N{43PyCwTR?=NFXpUJRUSU6JRWK=
C32MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF[2V3RKSzVyPUWzMlg{KG6PM4C2dHNCVkeHUh?=
GB-1NETFOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\WRZFUUUN3ME21OE4zKG6PMor3V2FPT0WU
SNB75M4DkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XSdGlEPTB;NUSuNlYhdk1?MXjTRW5ITVJ?
EM-2MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\rS2lEPTB;NUSuOEBvVQ>?NF;KfXRUSU6JRWK=
RH-1NHPwToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLPOXBKSzVyPUW0Mlchdk1?NXrW[m91W0GQR1XS
NKM-1NWnWc3M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\3O2lEPTB;NUSuPFEhdk1?NIjLcm9USU6JRWK=
NCI-H2405NYjBNGdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTV2Lki4JI5ONWrZWJZ1W0GQR1XS
KYSE-450NXrUeWFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7sdIVKSzVyPUW1MlE3KG6PNGPtNJlUSU6JRWK=
A704NE\4WY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17ZXmlEPTB;NUWuOVkhdk1?MkfOV2FPT0WU
HAL-01M2f1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlT2TWM2OD13NT64N{BvVQ>?MX7TRW5ITVJ?
TE-11MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPUcFhKSzVyPUW1Mlk6KG6PNHzlRpRUSU6JRWK=
DOKNYrXbWR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nDdmlEPTB;NU[uNFIhdk1?MYrTRW5ITVJ?
KY821NYLDTndET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\o[4dKSzVyPUW2MlIhdk1?NVfUVWNHW0GQR1XS
KGNMlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTV4LkOyJI5OM2LNPXNCVkeHUh?=
MC116M3XNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\UPW9KSzVyPUW3Mlghdk1?MVPTRW5ITVJ?
PANC-08-13NYPTUGJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHXXVVpUUN3ME21PE4xOSCwTR?=NFXwclZUSU6JRWK=
KE-37MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rU[2lEPTB;NUiuO|chdk1?NGPRO4VUSU6JRWK=
KYSE-410MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7sWZNKSzVyPUW5MlQ4KG6PNX:zfnZFW0GQR1XS
RO82-W-1M33ubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTV7Lkmgcm0>NHTIfplUSU6JRWK=
M14MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LFZWlEPTB;NkCuNFQhdk1?MkfqV2FPT0WU
GI-1NHvVPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWmyUJhTUUN3ME22NE4{KG6PMVTTRW5ITVJ?
ML-2MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjhTWM2OD14MD62NkBvVQ>?MmjIV2FPT0WU
BFTC-905MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTZyLk[1JI5OMV7TRW5ITVJ?
DMS-273NGLVPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XBR2lEPTB;NkCuPFchdk1?MnHUV2FPT0WU
MDA-MB-361M3ewTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXpVZJKSzVyPU[xJI5OM1LOSHNCVkeHUh?=
MSTO-211HMorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTZ|LkWxJI5OMXfTRW5ITVJ?
MEG-01MnH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDpTWM2OD14Mz61NkBvVQ>?NXnX[3h5W0GQR1XS
M059JMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVO0PVJIUUN3ME22N{42QCCwTR?=MWjTRW5ITVJ?
LN-405MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fFXGlEPTB;NkOuPFUhdk1?M3zoVHNCVkeHUh?=
NCI-H1581MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTZ2LkCzJI5OM1X0PXNCVkeHUh?=
TCCSUPM4rNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7pTWM2OD14ND61N{BvVQ>?M1TYeXNCVkeHUh?=
SW872MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;FU2lEPTB;NkSuOVchdk1?NXHiVmViW0GQR1XS
KYSE-510MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTZ3Lke1JI5ONETBU4tUSU6JRWK=
NCI-H1792MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLmUmY3UUN3ME22Ok4yPSCwTR?=NVTaSpBIW0GQR1XS
SW13MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnf0TWM2OD14Nj61JI5OMnT2V2FPT0WU
TE-8NWXMfm9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlu4TWM2OD14Nj61NkBvVQ>?MoTnV2FPT0WU
SCHNW\GPGFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jFNmlEPTB;NkeuNUBvVQ>?MVjTRW5ITVJ?
NEC8MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF:yUFVKSzVyPU[3MlI1KG6PMnLiV2FPT0WU
HuO-3N1NEDTVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrxOIVJUUN3ME22O{4{OSCwTR?=MXfTRW5ITVJ?
EFM-19MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTZ5LkWgcm0>NGHZepZUSU6JRWK=
HEC-1Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHBdFRKSzVyPU[3MlUzKG6PMkXVV2FPT0WU
T47DNY\SR3l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7XUVFKSzVyPU[3Mlg4KG6PMl7tV2FPT0WU
SNU-423MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{Xib2lEPTB;NkeuPVghdk1?M1[2PHNCVkeHUh?=
WM-115NFjnd5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH:yNJJKSzVyPU[4MlE1KG6PM{LiSnNCVkeHUh?=
CaR-1M3rST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDVTWM2OD14OD6yOUBvVQ>?MVLTRW5ITVJ?
KU812MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTZ6Lk[5JI5OM2nMb3NCVkeHUh?=
AM-38NVjCXFJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTZ7LkOxJI5OMX\TRW5ITVJ?
KOSC-2NFX3PJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TFWWlEPTB;NkmuPVchdk1?MoTqV2FPT0WU
MC-IXCMn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTdyLkC4JI5OMn7xV2FPT0WU
SCC-4Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvWZVZKSzVyPUexMlM5KG6PM{P0[HNCVkeHUh?=
Calu-3MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XoN2lEPTB;N{GuPVghdk1?NGDROVlUSU6JRWK=
RPMI-8866NXnQXYU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTd{LkiyJI5OMl31V2FPT0WU
OVCAR-4NGLoTJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\pR2lEPTB;N{OuN|Yhdk1?M4TzXnNCVkeHUh?=
OAW-42M4\TXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTd|LkO5JI5OM3PHN3NCVkeHUh?=
ATN-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTd|Lki3JI5OMnrJV2FPT0WU
CHP-212NGq3cXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fXcWlEPTB;N{SuPVUhdk1?NYXpXo1lW0GQR1XS
C2BBe1NXzOTW1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvmZ5NLUUN3ME23OU4xOyCwTR?=MYXTRW5ITVJ?
A498NYezVGFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH:3WpJKSzVyPUe1MlE2KG6PM1i4PHNCVkeHUh?=
SH-4NWDqeZU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTOXoVKSzVyPUe1MlIyKG6PNHHSOWtUSU6JRWK=
SNU-449MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHvT|Y2UUN3ME23OU44QSCwTR?=Ml\rV2FPT0WU
RDNE\j[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTd3Lki2JI5ONX;GV5JPW0GQR1XS
PANC-03-27NYf6TphtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfMdGxbUUN3ME23Ok4zPSCwTR?=MmrvV2FPT0WU
S-117M3zTfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTd4LkK3JI5OMk\tV2FPT0WU
SK-MEL-2M{fCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1X3ZmlEPTB;N{[uO|Uhdk1?NF:4SIRUSU6JRWK=
LK-2NEHFPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTd5LkC1JI5OM3TjZ3NCVkeHUh?=
CP50-MEL-BMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVOwUHhoUUN3ME23O{41KG6PMV7TRW5ITVJ?
647-VNXzNOVBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DWemlEPTB;N{iuNFchdk1?MV\TRW5ITVJ?
LU-134-ANE\hZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfETWM2OD15OT6wN{BvVQ>?NGL2elRUSU6JRWK=
5637MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33j[2lEPTB;N{muNlMhdk1?NFHkcHJUSU6JRWK=
NCI-H1437NXrETlB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4X3e2lEPTB;OECuOUBvVQ>?MYDTRW5ITVJ?
NCI-H460M1jSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRThzLkKzJI5OMXTTRW5ITVJ?
BxPC-3M4LJTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRThzLkS2JI5OMWnTRW5ITVJ?
CANMkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\ycWlEPTB;OEGuPFQhdk1?M2fDeHNCVkeHUh?=
KINGS-1NEfwT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoewTWM2OD16Mj6zNkBvVQ>?MUnTRW5ITVJ?
OCUB-MNVPaTHdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTh{LkSxJI5OMnHhV2FPT0WU
KALS-1M1LOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTh{LkW0JI5ONHzvb3dUSU6JRWK=
OCI-AML2M{fuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzy[|VWUUN3ME24Nk43OSCwTR?=MnK3V2FPT0WU
A253M33JNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEn1V|NKSzVyPUiyMlY2KG6PM4LSZnNCVkeHUh?=
LCLC-97TM1MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTh{Lki2JI5OMmDFV2FPT0WU
NCI-H520NUHNO2JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHVXnFyUUN3ME24N{4xPiCwTR?=NVLuXVZ3W0GQR1XS
P30-OHKNXSyeWZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTh|LkWgcm0>M{H5UnNCVkeHUh?=
SBC-5MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGi3S4ZKSzVyPUizMlUzKG6PNX7v[Xl1W0GQR1XS
HCE-TNHWy[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTh|Lke0JI5OMlLvV2FPT0WU
JEG-3M{XCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXpbpZNUUN3ME24OE4yKG6PMVnTRW5ITVJ?
KG-1M2flUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjkfmpKSzVyPUi0MlI1KG6PNVLoZph[W0GQR1XS
MIA-PaCa-2NIHSd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTh2LkW0JI5ONVXibFRVW0GQR1XS
CAL-33MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\RN3djUUN3ME24OU4xQCCwTR?=NIfHeZJUSU6JRWK=
639-VMlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\KTWM2OD16NT60NkBvVQ>?M1TTeHNCVkeHUh?=
NCI-H1048MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlrRTWM2OD16Nj6zNUBvVQ>?NIDS[5RUSU6JRWK=
NCI-H1573M{n3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrHTWM2OD16Nz60PEBvVQ>?Mk\MV2FPT0WU
NCI-H2228M4fEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWr6O4F{UUN3ME24PE4zPiCwTR?=MX\TRW5ITVJ?
NB14NFzSTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HoUWlEPTB;OEiuN{BvVQ>?Mm\pV2FPT0WU
SCC-25M4S0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTh7LkiyJI5OMXTTRW5ITVJ?
A431NYWzTWw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LoemlEPTB;OEmuPVchdk1?NWrCd3duW0GQR1XS
SN12CM3z4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTlyLk[yJI5OMX;TRW5ITVJ?
HuCCT1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjFWHV3UUN3ME25NE44PiCwTR?=MlLHV2FPT0WU
LS-123MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXHTWM2OD17Mj6xPEBvVQ>?NITNXopUSU6JRWK=
CAL-85-1M3LqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfn[WFkUUN3ME25Nk41QCCwTR?=Mnv5V2FPT0WU
ES6MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\O[2VFUUN3ME25Nk45OyCwTR?=NYPBSXBSW0GQR1XS
NCI-H650NVXOdmtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLQPVRKSzVyPUm0MlA6KG6PNILrTJJUSU6JRWK=
NCI-H446NIXHOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\ibGlEPTB;OUWuNVIhdk1?NYT5NG1[W0GQR1XS
EW-13NYHDbVF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4Xkc2lEPTB;OUWuO|Uhdk1?NVHBd3FvW0GQR1XS
HSC-2MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LLd2lEPTB;OUWuPFkhdk1?NVHKVVlxW0GQR1XS
U031MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzvTIt5UUN3ME25Ok44OyCwTR?=NVzrVWUyW0GQR1XS
EW-11NGi2XIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTl4Lki4JI5ONXjmW4dJW0GQR1XS
GAKMnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jOXGlEPTB;OUiuPVMhdk1?MmDjV2FPT0WU
SK-OV-3NVTWT5BST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLuTFdKSzVyPUGwNE4xPyCwTR?=M3jnU3NCVkeHUh?=
OMC-1NVHS[GRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIX2NpFKSzVyPUGwNE4yQCCwTR?=NFzDTGdUSU6JRWK=
TK10NXLPbllRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTFyMD6yNUBvVQ>?MU\TRW5ITVJ?
EKVXMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTFyMD62JI5ONULob2lwW0GQR1XS
Detroit562Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\tSIdKSzVyPUGwNk4yPyCwTR?=NIjoV|ZUSU6JRWK=
SF268NHXzW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnzR5VSUUN3ME2xNFIvOzRibl2=NXTrSlR3W0GQR1XS
SNU-387M3;uT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jKeWlEPTB;MUC0MlE4KG6PMYjTRW5ITVJ?
MDA-MB-231M{W3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGj4eppKSzVyPUGwOU4xPiCwTR?=NXjEdYkzW0GQR1XS
NCI-H1563MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjUTWM2OD1zMEWuNVghdk1?MVvTRW5ITVJ?
D-502MGMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXwW2xKSzVyPUGwOU44KG6PMoTUV2FPT0WU
A2780MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTBTWM2OD1zME[uOFchdk1?NHrWTo1USU6JRWK=
IA-LMM3TwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHr2To5KSzVyPUGwO{42OSCwTR?=MmnHV2FPT0WU
D-392MGNX3pWWRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInSe4RKSzVyPUGwO{42PCCwTR?=M1LXT3NCVkeHUh?=
MS-1M2TISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrtTmp{UUN3ME2xNFcvPzFibl2=NUSzOVNqW0GQR1XS
SW1990M{nZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;vTWM2OD1zMEiuOVQhdk1?NV3VS5U{W0GQR1XS
HELM{\tUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;zRpJKSzVyPUGwPU4zQSCwTR?=M3z6XHNCVkeHUh?=
SW1573M2DCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLpbnhtUUN3ME2xNFkvOzFibl2=NVX0Z3AyW0GQR1XS
SW1783M4m1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rvZmlEPTB;MUGwMlIzKG6PM33DXnNCVkeHUh?=
COLO-680NMnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3v6cmlEPTB;MUGwMlc3KG6PMnfTV2FPT0WU
NCI-N87NWj3Nok5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2O3TWlEPTB;MUGxMlA1KG6PMn\wV2FPT0WU
SK-MEL-28NY[1WoFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfVNoNKSzVyPUGxNU42PSCwTR?=NG\BWZVUSU6JRWK=
BT-20NXnYb41uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvjVmJ2UUN3ME2xNVIvODFibl2=NYG1RVhEW0GQR1XS
NCI-H1648NILmbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTFzMzDuUS=>M2TaPXNCVkeHUh?=
no-11M3LF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4fDdmlEPTB;MUGzMlI5KG6PMXvTRW5ITVJ?
MOLT-13M1rr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHLbWVKSzVyPUGxN{41PCCwTR?=NF3nbJhUSU6JRWK=
NCI-H2170NVrvWWxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLJTWM2OD1zMUSuOVEhdk1?NGTwWGFUSU6JRWK=
HTC-C3M2[wWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLDTWM2OD1zMU[uPFUhdk1?NVnXS5dzW0GQR1XS
LU-99AMoe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTFzNz6yNUBvVQ>?Mk\pV2FPT0WU
HCC2998MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXVTWM2OD1zMUeuPVIhdk1?MYfTRW5ITVJ?
NB13MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PHUmlEPTB;MUG3Mlk6KG6PMlH2V2FPT0WU
GT3TKBNG\i[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIe3XVJKSzVyPUGxPE4xQCCwTR?=Mo[4V2FPT0WU
BT-549MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUj3ZZVwUUN3ME2xNVgvQTVibl2=MYrTRW5ITVJ?
NCI-H747M{LKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LZRWlEPTB;MUG5MlM1KG6PMnHWV2FPT0WU
EW-1NV7wc3lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{O4V2lEPTB;MUKwMlIhdk1?MXjTRW5ITVJ?
LB831-BLCMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHpTWM2OD1zMkCuOlMhdk1?M3HZdHNCVkeHUh?=
NMC-G1Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTF{MT6xNUBvVQ>?MmHhV2FPT0WU
COLO-679MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTF{Mj6xOUBvVQ>?NF\kfFhUSU6JRWK=
HL-60M{fWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFWyOWFKSzVyPUGyN{4yKG6PMknwV2FPT0WU
MKN7Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTF{Mz64N{BvVQ>?M{HPNXNCVkeHUh?=
RERF-LC-MSMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDzW|FKSzVyPUGyOE4{OSCwTR?=NVSxXVJ6W0GQR1XS
DMS-114NUWxSG5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTF{NT6wPUBvVQ>?NYHvUngyW0GQR1XS
HuP-T4MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTF{Nj65O{BvVQ>?MojiV2FPT0WU
HCC2157M3LBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nnfmlEPTB;MUK3MlUhdk1?M2e4PXNCVkeHUh?=
SKG-IIIaM2fnZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlH3TWM2OD1zMkiuPEBvVQ>?MXvTRW5ITVJ?
HCT-116NVXL[GN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnTb5dKSzVyPUGzNE43PCCwTR?=NI\yd2JUSU6JRWK=
BB30-HNCMln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\1TWM2OD1zM{CuO|ghdk1?NXvC[IttW0GQR1XS
KYSE-270MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGWxUZlKSzVyPUGzNE45QCCwTR?=M1HnWXNCVkeHUh?=
MFM-223NVHZd2VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTF|MT61NUBvVQ>?MWPTRW5ITVJ?
NH-12M1rjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETxSGhKSzVyPUGzNk46QSCwTR?=Mn7ZV2FPT0WU
U-118-MGNGTlW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHBTWM2OD1zM{OuOlIhdk1?NGC5PYZUSU6JRWK=
ESS-1NXXGXmM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTF|NT6xPEBvVQ>?MVTTRW5ITVJ?
D-247MGNXHVeXA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MknRTWM2OD1zM{WuNlEhdk1?M{HRPHNCVkeHUh?=
IGROV-1MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjOOoNjUUN3ME2xN|UvPzZibl2=M3;QOnNCVkeHUh?=
C-33-AMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XP[WlEPTB;MUO1Mlk4KG6PNEXmbIlUSU6JRWK=
NCI-H1693MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTF|Nj6xNkBvVQ>?Ml;NV2FPT0WU
MLMAMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHLeItKSzVyPUGzOk42QCCwTR?=NUW1NXZVW0GQR1XS
SK-N-ASMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTF|Nz6xO{BvVQ>?NFH4So5USU6JRWK=
NCI-H1755NEO4fohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTF|OD64OUBvVQ>?MWnTRW5ITVJ?
CHP-134MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4CzTGlEPTB;MUO5MlU2KG6PMUnTRW5ITVJ?
LS-513MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTlTWM2OD1zNECuPVEheE1?MXvTRW5ITVJ?
TE-12NVrleY5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTF2MD65N{BvVQ>?MnjZV2FPT0WU
KNS-42M3TzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3qOI9DUUN3ME2xOFQvOyCwTR?=NYLEdIhoW0GQR1XS
SJRH30NVfFUnR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXzTWNtUUN3ME2xOFQvPDRibl2=MlX1V2FPT0WU
NCI-H1092MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHkcGxNUUN3ME2xOFQvPTJibl2=M{Xz[nNCVkeHUh?=
H-EMC-SSM3i5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPRTWM2OD1zNE[uPFEhdk1?MYLTRW5ITVJ?
SK-MEL-3M3P5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLOR3dZUUN3ME2xOFcvPTVibl2=M2XVOnNCVkeHUh?=
SK-N-FIMkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTF2Nz61PUBvVQ>?MUDTRW5ITVJ?
NCI-H2126Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7vNWYxUUN3ME2xOFgvOTVibl2=MWPTRW5ITVJ?
NCI-H1299NEDMcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTF3MD6yNkBvVQ>?Mm\BV2FPT0WU
CFPAC-1NHK0eYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTF3MD62OkBvVQ>?MoLwV2FPT0WU
NCI-H661MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELMcHpKSzVyPUG1NU4zPiCwTR?=M2fx[3NCVkeHUh?=
KYSE-70MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorHTWM2OD1zNUGuO|khdk1?MXvTRW5ITVJ?
SW900NV7KWGRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3P6cWlEPTB;MUW0MlY2KG6PMX\TRW5ITVJ?
Ca-SkiMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3u0dWlEPTB;MUW2MlM6KG6PM1PmeHNCVkeHUh?=
HPAF-IIMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LMXWlEPTB;MUW2MlQ4KG6PNXTEZpdVW0GQR1XS
LB2518-MELNWHkPJd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvEcGQ4UUN3ME2xOVcvOSCwTR?=MojOV2FPT0WU
LC-2-adMnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmP3TWM2OD1zNUiuOlIhdk1?MYnTRW5ITVJ?
HCC1806NGfzV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLLZ5JkUUN3ME2xOlcvQDhibl2=M2fJenNCVkeHUh?=
UACC-62NWS0UVdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVP6eo5vUUN3ME2xOlgvODlibl2=NETzWoFUSU6JRWK=
KM-H2MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37xdGlEPTB;MUewMlU5KG6PMWPTRW5ITVJ?
NCI-H2347NFHpdFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn21TWM2OD1zN{KuO|Ihdk1?NF3XTYxUSU6JRWK=
SCC-15NH22blJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TTNmlEPTB;MUezMlY3KG6PNUiwOZQ4W0GQR1XS
BB49-HNCMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jmOWlEPTB;MUezMlgyKG6PNEnrPIlUSU6JRWK=
GMS-10M3LCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTF5Mz65OEBvVQ>?M{HDPXNCVkeHUh?=
NCI-H2052M4LDWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfISGlKSzVyPUG3OE46KG6PMVHTRW5ITVJ?
SW626NWPSSmZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTF5Nj6wOkBvVQ>?Mnn0V2FPT0WU
MDA-MB-415NYXkVoN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TxT2lEPTB;MUe2MlYyKG6PMn7vV2FPT0WU
Saos-2M2X1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDjSWp1UUN3ME2xO|kvOzVibl2=MonnV2FPT0WU
DK-MGNXvNWmJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnJOldKSzVyPUG4NE4{KG6PMX7TRW5ITVJ?
SNU-C2BMnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3H1V2lEPTB;MUiwMlc{KG6PM1q1RnNCVkeHUh?=
A427MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDNTWM2OD1zOEKuOVchdk1?M1X2PHNCVkeHUh?=
KP-N-YSNILsRmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTF6NTDuUS=>MmCyV2FPT0WU
J82NWXER2ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTPVIpbUUN3ME2xPFUvOThibl2=NU\3U|ltW0GQR1XS
LS-411NNXT3[o5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfJWHdKSzVyPUG4O{4zQCCwTR?=NWrRfFV3W0GQR1XS
HCC1937NVXUfJhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4S3NWlEPTB;MUi3MlQ6KG6PNXW3NHlQW0GQR1XS
OE33NHPDc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlntTWM2OD1zOEiuPVchdk1?M2fhe3NCVkeHUh?=
NB7M2HJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHG1RoFKSzVyPUG4PU45QSCwTR?=NYTlclZiW0GQR1XS
SW684MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2DWNmlEPTB;MUm2MlE{KG6PNGnYdFJUSU6JRWK=
HT-144MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnGTWM2OD1zOU[uNVUhdk1?NGm2OHRUSU6JRWK=
SK-MEL-30NVj2PIJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjOd5dwUUN3ME2xPVYvOiCwTR?=NELCW2hUSU6JRWK=
DBTRG-05MGNWr4V|d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrOclNkUUN3ME2xPVgvPDdibl2=Mn\ZV2FPT0WU
NCI-H1395NHTDZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTF7OD64OUBvVQ>?NFLEfHVUSU6JRWK=
NCI-H2122MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTJyMD61PUBvVQ>?NVfLZnRCW0GQR1XS
no-10NULESZBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTJyMT6wOEBvVQ>?MVfTRW5ITVJ?
SW48NF7R[|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHvWnNKSzVyPUKwNU4{OSCwTR?=NUT0OGRbW0GQR1XS
NCI-H1650M1jRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NECwN3FKSzVyPUKwOE4xOSCwTR?=MmG0V2FPT0WU
MZ1-PCMkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUCwO2NRUUN3ME2yNFUvPThibl2=M1i3bXNCVkeHUh?=
U-266NGLYR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTJyNT63PUBvVQ>?M2r1SHNCVkeHUh?=
CAS-1M4i2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nvUmlEPTB;MkC3MlQ1KG6PNIDIeHhUSU6JRWK=
AU565MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXY[WxlUUN3ME2yNVIvQDJibl2=NELmNlNUSU6JRWK=
UACC-257MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoroTWM2OD1{MUOuPVkhdk1?NELqOGZUSU6JRWK=
CAL-27NHL1R4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkG0TWM2OD1{MUeuNFUhdk1?NGjQOIFUSU6JRWK=
NCI-H23NGXNfFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLmTWM2OD1{MUmuN|Mhdk1?NYfhU3hGW0GQR1XS
TE-6M3zteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXUTWM2OD1{MUmuOlghdk1?M1jDU3NCVkeHUh?=
TGBC24TKBNWrXOGVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzETWM2OD1{MkKuNVchdk1?NXvKVXJ7W0GQR1XS
TE-1NXy1SFdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml33TWM2OD1{MkKuPFghdk1?NXLOdYdbW0GQR1XS
RCC10RGBMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkD6TWM2OD1{MkSuNVkhdk1?NFG5SGpUSU6JRWK=
NCI-H596Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmT2TWM2OD1{MkiuNlIhdk1?NYjrSXFoW0GQR1XS
SW954M2HiVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DFeGlEPTB;MkOzMlg{KG6PNFzJZphUSU6JRWK=
NCI-H2087NXznW4FzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTpdnBjUUN3ME2yN|QvPTFibl2=MWjTRW5ITVJ?
SK-PN-DWNGTGS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml73TWM2OD1{M{WuNVkhdk1?NIDYZ3ZUSU6JRWK=
KM12NWX3UXVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjlV2tKSzVyPUKzOU44KG6PNYraXFc6W0GQR1XS
BT-474MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLJPFBEUUN3ME2yN|UvPzNibl2=M{C3UXNCVkeHUh?=
IST-MES1NXG3OGdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTJ|Nj61O{BvVQ>?NWrpeo9sW0GQR1XS
HT-1197NXjGbHlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTJ|OD6wPUBvVQ>?MoS1V2FPT0WU
CAL-54NVXLdplLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXsPWVNUUN3ME2yN|gvPDlibl2=NIr3S5pUSU6JRWK=
NB10NWX2bFgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTJ2MD6wOkBvVQ>?MV;TRW5ITVJ?
PANC-10-05M33KOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37GbmlEPTB;MkS1MlU3KG6PNYLMWmVNW0GQR1XS
NCI-H522M1jNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\HeGlKSzVyPUK0PE4{OSCwTR?=NWW2WYlEW0GQR1XS
A388MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;ncpRHUUN3ME2yOFkvQDJibl2=MUnTRW5ITVJ?
GOTOMnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEL0NGhKSzVyPUK1NE4zQSCwTR?=MVHTRW5ITVJ?
KLENXW5TmlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrKTWM2OD1{NUGuPFchdk1?NWj5[5hCW0GQR1XS
KYSE-520MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDiVmFKSzVyPUK1Nk45PiCwTR?=NYe1eJJ2W0GQR1XS
HCE-4MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYe0TpVQUUN3ME2yOlIvPSCwTR?=NX7wd|U2W0GQR1XS
KURAMOCHIMn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTJ4NT65JI5ONGrxRYdUSU6JRWK=
HCC38NFq2U4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfRdXAxUUN3ME2yOlYvPDhibl2=M4LGO3NCVkeHUh?=
FADUNG\LUldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTtTWM2OD1{Nk[uOlMhdk1?NHjEPGNUSU6JRWK=
CW-2M3;5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTJ4OT65OkBvVQ>?MVfTRW5ITVJ?
L-428MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXmenZKSzVyPUK3OU4yPSCwTR?=NXzYNHhsW0GQR1XS
HCC1569NVixRXhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTJ5NT64OEBvVQ>?M1jFTnNCVkeHUh?=
NCI-H810MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIr1XWdKSzVyPUK3PE4{OSCwTR?=MkXOV2FPT0WU
LB771-HNCM3HkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPpTWM2OD1{OEWuPFQhdk1?M{SxN3NCVkeHUh?=
LCLC-103HNIX0dlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTJ6NT65PUBvVQ>?MmDQV2FPT0WU
EFO-21M3;ieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTKTWM2OD1{OEeuOlghdk1?MUfTRW5ITVJ?
CAL-72MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTpNVdKSzVyPUK5N{4yQSCwTR?=NEX4XVlUSU6JRWK=
SCC-9MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTJ7Mz6yNkBvVQ>?MUXTRW5ITVJ?
COLO-829NVXMNINIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\UR4JKSzVyPUK5Ok42KG6PM3LmVnNCVkeHUh?=
U-87-MGMmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTNyMD63N{BvVQ>?NFvOOWtUSU6JRWK=
MZ7-melMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DxUmlEPTB;M{KzMlc3KG6PNX\GO2lGW0GQR1XS
NCI-H1770MnPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLKOWhKSzVyPUOyOk44PCCwTR?=M1T1NnNCVkeHUh?=
ChaGo-K-1NUnsOFFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTN{OD6xJI5OM2njXnNCVkeHUh?=
SiHaM{jYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjiNHJKSzVyPUOyPU4zPCCwTR?=MVnTRW5ITVJ?
NCI-SNU-5MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\mTWM2OD1|M{[uO|chdk1?NXjYfJNlW0GQR1XS
DJM-1NFrOfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\G[2lEPTB;M{SwMlM{KG6PNGSwd3FUSU6JRWK=
OE19M4\QeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI[5SGhKSzVyPUO0NE42OyCwTR?=NEKxb4NUSU6JRWK=
NCI-H1651NFTvdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1OxNWlEPTB;M{S0MlE5KG6PMlXuV2FPT0WU
COLO-792M1LTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HNWmlEPTB;M{W0MlQzKG6PMUHTRW5ITVJ?
ACHNM1;NfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXrOI9sUUN3ME2zOVYvPzFibl2=MoT6V2FPT0WU
TH-3MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorLTWM2OD1|N{muPVUhdk1?NHTzZXhUSU6JRWK=
HT-1376MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTN6ND64PEBvVQ>?NFXCNodUSU6JRWK=
RH-18MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTN7ND63OEBvVQ>?MXHTRW5ITVJ?
NB6NIWyWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfRXolwUUN3ME2zPVYvPjZibl2=NUDYcoViW0GQR1XS
COLO-320-HSRMn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjQRWtNUUN3ME20NFMvOzdibl2=MmjIV2FPT0WU
UACC-893NGDiVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrKRYVKSzVyPUSwOk41PyCwTR?=MkHIV2FPT0WU
DSH1NFz6RXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTRyNj65NUBvVQ>?NYrqSZFMW0GQR1XS
TE-10MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInlUZFKSzVyPUSwO{4xOSCwTR?=NEfKTo9USU6JRWK=
HCC70M2P0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3n4fWlEPTB;NEC5MlIyKG6PMlvOV2FPT0WU
TGBC11TKBM2KwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUH6fWlIUUN3ME20NVAvOzNibl2=MlGyV2FPT0WU
NCI-H727M3TUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELGS45KSzVyPUSxNk4yOSCwTR?=NVHsO21HW0GQR1XS
ALL-POMkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTRzNT62PUBvVQ>?NYfi[|BGW0GQR1XS
ABC-1MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MonlTWM2OD12MkCuOFUhdk1?Mk\kV2FPT0WU
NCI-H69MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HDXWlEPTB;NEK2Mlc3KG6PMYLTRW5ITVJ?
GP5dNGfVWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnr[VJKSzVyPUSzOE41OSCwTR?=MmfZV2FPT0WU
UMC-11Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTR3OD6zOkBvVQ>?MkP6V2FPT0WU
RMG-IM3Xudmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{Lkb2lEPTB;NE[3MlU3KG6PM2fBVHNCVkeHUh?=
YAPCMmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;5TWM2OD12OUCuOkBvVQ>?MmX3V2FPT0WU
LS-1034MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4D3ZWlEPTB;NEmxMlA3KG6PM2DDS3NCVkeHUh?=
RCM-1MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTR7Nj62PEBvVQ>?NFvBPINUSU6JRWK=
HCC1954M1zObGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHmeYZKSzVyPUWxNk42KG6PNFLONoZUSU6JRWK=
SK-MEL-24NVPwN2R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33MemlEPTB;NUG2MlUyKG6PNYm4c|B7W0GQR1XS
NB12MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTme25XUUN3ME21NlgvPDJibl2=M3jx[XNCVkeHUh?=
SW756MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHn4c|ZKSzVyPUW1OE46PiCwTR?=M3Lp[HNCVkeHUh?=
HCC1187MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2izWGlEPTB;NUe1Mlg{KG6PMormV2FPT0WU
NCI-H2342M3Lhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPsUWJLUUN3ME21PVAvOzlibl2=NInTOVJUSU6JRWK=
NCI-H2291MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\Qe|ZKSzVyPUW5PE4{OSCwTR?=Mn3OV2FPT0WU
OVCAR-3M3TDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rGT2lEPTB;NUm4Mlk3KG6PMVXTRW5ITVJ?
MHH-NB-11MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fX[mlEPTB;NkK5MlAyKG6PNWjwV4M5W0GQR1XS
SASMnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTZ3Mj62O{BvVQ>?NH3zbI5USU6JRWK=
COLO-824NUjqTItOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4K0TGlEPTB;Nki5MlM4KG6PNV;Hd3d6W0GQR1XS
HCC1395Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHHhS45KSzVyPU[5PE42KG6PMVPTRW5ITVJ?
COLO-668NVnNT5NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzlZnNKSzVyPUewOk4yKG6PMWPTRW5ITVJ?
NCI-H226NH7NUJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrPV|dKSzVyPUewO{45KG6PMoP3V2FPT0WU
NB17NXXBb3JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLyPFBKSzVyPUeyNU44PSCwTR?=Mne1V2FPT0WU
SW1463MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jh[2lEPTB;N{O5MlE6KG6PNEG3[GtUSU6JRWK=
TGWMl3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUTs[Jd6UUN3ME23OlAvOTVibl2=NVLhZXlWW0GQR1XS
NCI-H526M3WwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{L6dWlEPTB;OEKzMlU{KG6PMWfTRW5ITVJ?
COR-L88Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3j6UGlEPTB;OES4MlEzKG6PNYrNepA5W0GQR1XS
NCI-H441MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX65U49pUUN3ME24PVUvOjJibl2=NFXDNZlUSU6JRWK=
NCI-H630M4nYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jZS2lEPTB;OUGyMlk3KG6PNIHvc29USU6JRWK=
Mo-TMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHfLTXJKSzVyPUm0O{45QCCwTR?=MmDuV2FPT0WU
JARNX7aO2dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\lTWM2OD17NU[uNlQhdk1?MV7TRW5ITVJ?
NCI-H1838MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rJWGlEPTB;MT6wNlM5QCEQvF2=NEXyTm1USU6JRWK=
DoTc2-4510MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTFwMEezO|Yh|ryPMnvmV2FPT0WU
MKN28MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmHkTWM2OD1zLkC5NFI1KM7:TR?=MnLmV2FPT0WU
HuP-T3M4DzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTFwMUG5NFUh|ryPM1LP[nNCVkeHUh?=
TE-9M3vSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHjTWM2OD1zLkGyPVc{KM7:TR?=NVLP[mVyW0GQR1XS
NYNVLwV4MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILVeVRKSzVyPUGuNVY4QTJizszNNXvDcoNxW0GQR1XS
HT55NEjhPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHUeYZKSzVyPUGuN|E{PDRizszNNWLG[m9ZW0GQR1XS
SW837NH[zPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTFwM{K5O|gh|ryPMoXMV2FPT0WU
NCI-H2029M2LVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTFwNEG3PVEh|ryPMXLTRW5ITVJ?
IST-SL1NGjsTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonRTWM2OD1zLkS0NlQh|ryPM3vkRXNCVkeHUh?=
COLO-741M3iwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mkj4TWM2OD1zLkS5O|cyKM7:TR?=MoD3V2FPT0WU
LU-65MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzBTWM2OD1zLk[yNlQ6KM7:TR?=MUXTRW5ITVJ?
NCI-H1304NVK2SWR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjK[5lKSzVyPUGuOlU1QThizszNNGPpcI5USU6JRWK=
KARPAS-299MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTFwN{m0O|kh|ryPMk\MV2FPT0WU
NCI-H358NFraZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVeyU5lRUUN3ME2xMlk2PTB|IN88US=>MoT5V2FPT0WU
OAW-28NHjR[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfXbG06UUN3ME2yMlA3QTF7IN88US=>NGjCfY1USU6JRWK=
C8166MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrRSHZKSzVyPUKuOlM{QTJizszNM4Cwc3NCVkeHUh?=
COLO-678MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILzR|VKSzVyPUKuPFM4PjhizszNMkHVV2FPT0WU
SK-N-DZNGXWSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLVcnBIUUN3ME2yMlg3OzhzIN88US=>NYO4[3llW0GQR1XS
NCI-H82MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4T3cmlEPTB;Mj65NFM3QSEQvF2=M{TBTXNCVkeHUh?=
JVM-2M2q1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHyNnJKSzVyPUOuNFMyQDhizszNMVvTRW5ITVJ?
SW1116MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;uZlJkUUN3ME2zMlA2PDFzIN88US=>NVnpelhuW0GQR1XS
MDA-MB-453NHnKbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1LScWlEPTB;Mz6xNFQ{QSEQvF2=M3fVdXNCVkeHUh?=
Calu-6NGXZ[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTNwMUm5O{DPxE1?NVXZfGVoW0GQR1XS
SHP-77MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;mTWM2OD1|LkWyPEDPxE1?MYPTRW5ITVJ?
Capan-2NVz4eox4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\GTWM2OD12LkOyOVgyKM7:TR?=M2T1XXNCVkeHUh?=
SW948NYfWcG5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2ToS2lEPTB;ND63OFc4QSEQvF2=NEfvZ5BUSU6JRWK=
HDLM-2NYK2VlFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVX6TWI5UUN3ME21MlA4PzJ3IN88US=>M1PObHNCVkeHUh?=
LAN-6MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrpTWM2OD14LkKxOFk2KM7:TR?=MmLXV2FPT0WU
LU-135NHnvfXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLVUXpGUUN3ME22MlQ{ODd5IN88US=>NV:4c2tNW0GQR1XS
T84MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPrOY9vUUN3ME22Mlk5PjRizszNM1i5T3NCVkeHUh?=
CAPAN-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFfmfW1KSzVyPUeuOlIzOzNizszNM{TMS3NCVkeHUh?=
SW1417MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjVTmJKSzVyPUeuPVE4OzFizszNNUjKW2pvW0GQR1XS
BALL-1M4DoNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkT4TWM2OD16LkWwOFA6KM7:TR?=MnvQV2FPT0WU
HT-29NXm1cFM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4n3c2lEPTB;OT6wO|U6QSEQvF2=NUHm[oo6W0GQR1XS
C3AMomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\sOGlEPTB;OT64PFM6PCEQvF2=MV\TRW5ITVJ?
NCI-H1993NUTjNnVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTFyLkWwPFEh|ryPNILwOopUSU6JRWK=
SK-MEL-1Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2flfmlEPTB;MUGuOlI5QSEQvF2=NHW5dWlUSU6JRWK=
DU-145MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLOTWM2OD1zND61NFUzKM7:TR?=NH\SPXRUSU6JRWK=
KP-N-YNM4XvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljxTWM2OD1zND61NVA{KM7:TR?=NVL2[Id6W0GQR1XS
CCRF-CEMNVTIb49YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPROFNxUUN3ME2xOE44QDB7IN88US=>MUTTRW5ITVJ?
ZR-75-30MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vlNGlEPTB;MU[uN|MxOyEQvF2=NYHkPINbW0GQR1XS
A673NIO4UG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTJyLkW1NFch|ryPMn;GV2FPT0WU
K-562NYPNNGRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17GXmlEPTB;MkiuOFE5OyEQvF2=NUnJTmJQW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. [1]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

In vitro Protein Kinase, PI3K, and mTOR Assays PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH2-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.

Cell Assay:

[2]

Cell lines HCT116, DLD-1 and SW480 cells
Concentrations 0-1 μM
Incubation Time 48 hours
Method

The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 103 cells/well, DLD-1: 5.5 × 103 cells/well, SW480: 4.5 × 103 cells/well, DLD-1 PIK3CA mutant: 7 × 103 cells/well, and DLD-1 PIK3CA wild-type: 9 × 103 cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours.

Animal Study:

[1]

Animal Models Female Harlan athymic nude mice
Formulation NMP/polyethylene glycol 300 (10/90, v/v)
Dosages 45 mg/kg
Administration p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Maira SM, et al. Mol Cancer Ther, 2008, 7(7), 1851-1863.

[2] Roper J, et al. PLoS One, 2011, 6(9), e25132.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01856101 Terminated Carcinoma Transitional Cell Cliniques universitaires Saint-Luc- Université Catholique  ...more Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Novartis February 2013 Phase 2
NCT01717898 Terminated Castrate-resistant Prostate Cancer Patients. Charles Ryan|Novartis Pharmaceuticals|University of Calif  ...more Charles Ryan|Novartis Pharmaceuticals|University of California, San Francisco January 2013 Phase 1|Phase 2
NCT01658436 Completed Pancreatic Neuroendocrine Tumors (pNET) Novartis Pharmaceuticals|Novartis November 2012 Phase 2
NCT01628913 Terminated Pancreatic Neuroendocrine Tumors (pNET) Novartis Pharmaceuticals|Novartis October 2012 Phase 2
NCT01690871 Withdrawn Malignant PEComa (Perivascular Epithelioid Cell Tumors) Novartis Pharmaceuticals|Novartis September 2012 Phase 2

view more

Chemical Information

Download BEZ235 (NVP-BEZ235, Dactolisib) SDF
Molecular Weight (MW) 469.55
Formula

C30H23N5O

CAS No. 915019-65-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMF 18 mg/mL warming (38.33 mM)
DMSO 0.01 mg/mL (0.02 mM)
Water <1 mg/mL (<1 mM)
In vivo NMP+polyethylene glycol 300 (10+90, v+v) 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile

Customer Product Validation(8)


Click to enlarge
Rating
Source Cancer Res 2010 70, 4982-4994. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Detection of lipid kinase activities of PI3K p110α mutants
Cell Lines HEK293T cells
Concentrations
Incubation Time
Results "Evaluation of relative kinase activity of these mutants revealed that mutant P449T exhibited gain of function (>2-fold) compared with wild-type PI3K α (Fig. A). With regard to two hotspot mutants (E545K and H1047R), we examined the effect of NVP-BEZ235 and other PI3K inhibitors on their enzymatic activity and found no striking difference in their efficacies compared with wild-type p110α (Fig. B).

Click to enlarge
Rating
Source Clin Cancer Res 2010 16, 6029-6039. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Synergism studies, Immunoblot assays, Clonogenic assays
Cell Lines Melanoma cell
Concentrations 0.1-100 μM
Incubation Time 1-24 h
Results One of the proposed mechanisms of resistance to PI3KIs is mutation in the Ras-Raf pathway, which are found in more than half of melanomas. By ANOVA, no association was found between the IC50 values of NVP-BEZ235 and the presence or absence of B-Raf mutations (Fig. A). The targets of NVP-BEZ235, pAkt and pP70S6K, were both decreased with exposure to the drug in a time- and dose-dependent fashion, as shown in Figure B for YUVON and YUSIK cell lines. Clonogenicity was studied in YUVON and YUSIK cells with exposure to the dual PI3K/mTOR inhibitor. As shown in Figure C, NVP-BEZ235 effectively inhibits clonogenicity at low nanomolar concentrations.

Click to enlarge
Rating
Source Breast Cancer Res 2011 13, R52. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Immunofluorescence staining
Cell Lines MCF7 cells, IGF1R cells
Concentrations
Incubation Time
Results We investigated the effect of IGF-1 stimulation on MCF7/IGF-1R 4-OH-TAM resistance in a structurally and physiologically relevant context by use of a modified 3D culture. Both parental MCF7 (Figure a) and MCF7/IGF-1R cells (Figure b) were responsive to E2 or IGF-1 by forming acini on Matrigel, but the response was significantly larger in MCF7/IGF-1R cells with altered a cinar morphogenesis. inhibition of IGF -1R/ERK/Akt signaling by respective kinase inhibitors restored 4-OH-TAM sensitivity of MCF7/IGF-1R cells in 3D culture (Figure c).

Click to enlarge
Rating
Source Breast Cancer Res 2011 13:R52. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Western blot, A sulforhodamine B ( SRB) colorimetric assay
Cell Lines MCF7 cells, GF-1R cells
Concentrations 0.01-10 μM
Incubation Time
Results IGF-1-stimulated proliferation was drastically restrained by BEZ235 at either 1 or 10 μM (Figure a).While IGF-1R and ERK signaling remained unaffected in response to IGF-1, the phosphorylation level of Akt was diminished with an increase in the dose of BEZ235, largely at 0.1 μM and entirely at 0.5 μM (Figure b). Likewise, the cell proliferation rate decreased correspondingly to Akt phosphorylation levels, significantly dropping at 0.1μM BEZ235 (Figure c)

Click to enlarge
Rating
Source Eur J Cancer 2010 46, 1111-1121. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method LanthaScreen assay
Cell Lines JFCR39 cell lines
Concentrations 0.016 μM
Incubation Time
Results As shown in Fig. A, NVP-BEZ235 and other inhibitors all inhibited mTOR in a dose-dependent manner. The IC50 values were calculated and are shown in Fig. B. NVP-BEZ235 inhibited mTOR potently, with IC50 value of 0.002 μM. In contrast, ZSTK474, GDC-0941 and LY294002 weakly inhibited mTOR, with IC50 values of 0.377, 0.413 and 3.86μM, respectively. To further demonstrate their selectivity for class I PI3K, the IC50 values of these inhibitors for mTOR were divided by their corresponding IC50s for class I PI3Ka, and the resulting ratios were plotted in Fig. C. Clearly, ZSTK474 and GDC-0941 revealed much higher selectivity for inhibiting class I PI3K than the other two inhibitors. In contrast, NVP-BEZ235 more potently inhibited the activity of mTOR than that of class I PI3K

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Western blot
Cell Lines breast cancer cells
Concentrations 0-10 nM
Incubation Time 3 h
Results

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Western blot
Cell Lines breast cancer cells
Concentrations 0-50 nM
Incubation Time 3 h
Results

Click to enlarge
Rating
Source BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Western Blotting
Cell Lines xenografts
Concentrations
Incubation Time
Results Phospholipase A2 group 4A (PLA2G4A) expression was increased after BEZ235 treatment in basal-like xenografts.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related PI3K Products

  • GDC-0032

    GDC-0032 is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with Ki of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.

  • Wortmannin

    Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

  • Alpelisib (BYL719)

    Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Recently Viewed Items

Tags: buy BEZ235 (NVP-BEZ235, Dactolisib) | BEZ235 (NVP-BEZ235, Dactolisib) supplier | purchase BEZ235 (NVP-BEZ235, Dactolisib) | BEZ235 (NVP-BEZ235, Dactolisib) cost | BEZ235 (NVP-BEZ235, Dactolisib) manufacturer | order BEZ235 (NVP-BEZ235, Dactolisib) | BEZ235 (NVP-BEZ235, Dactolisib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us